Enzon Pharmaceuticals, Inc. (ENZN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Enzon Pharmaceuticals, Inc. (ENZN) trades at $4.35 with AI Score 42/100 (Grade C). Enzon Pharmaceuticals, Inc. focuses on marketing drug products, primarily PegIntron. The company also has a marketing agreement relating to Vicineum drug. Market cap: $28.76M, Sector: Healthcare.
Price live · AI analysis from Jun 1, 2026Analyst Coverage for ENZN: ENZN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ENZN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ENZN: the 1 perspectives are evenly split.
How is this calculated? →Enzon Pharmaceuticals, Inc. (ENZN) Healthcare & Pipeline Overview
Enzon Pharmaceuticals, Inc., founded in 1981, operates within the biotechnology sector, marketing drug products like PegIntron and holding a marketing agreement for Vicineum. With a small team, the company navigates the healthcare landscape, focusing on its existing pharmaceutical assets.
What Is the Investment Thesis for ENZN?
Enzon Pharmaceuticals, Inc. presents a focused investment case centered on its existing drug product, PegIntron, and its marketing agreement for Vicineum. With a market capitalization of $28.76M and a negative profit margin of -11.1%, the company's financial performance requires careful evaluation. Key value drivers include the continued revenue generation from PegIntron and the potential upside from the Vicineum agreement. Growth catalysts may arise from strategic partnerships or market expansions, while potential risks include competition from other pharmaceutical products and regulatory changes. Investors should closely monitor the company's ability to manage its operational costs and maximize the value of its existing assets. The company's beta of -0.05 suggests a low correlation with the broader market, which could offer some portfolio diversification benefits.
Based on FMP financials and quantitative analysis
ENZN Key Highlights
- Market Cap of $28.76M indicates a small-cap company with limited market presence.
- Profit Margin of -11.1% reflects challenges in achieving profitability.
- Gross Margin of 9.8% suggests limited pricing power and high cost of goods sold.
- Beta of -0.05 indicates a low correlation with the overall market, potentially offering diversification benefits.
- The company's primary marketed drug product is PegIntron, representing a significant portion of its revenue.
Who Are ENZN's Competitors?
ENZN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ENZN's Key Strengths?
- Marketed drug product (PegIntron).
- Marketing agreement relating to Vicineum.
- Established presence in the biotechnology sector.
- Lean operational structure.
What Are ENZN's Weaknesses?
- Limited product portfolio.
- Negative profit margin.
- Small market capitalization.
- Reliance on a small number of employees.
What Could Drive ENZN Stock Higher?
- Potential strategic partnerships to expand market reach.
- Possible market expansion into new geographic regions.
- Lifecycle management strategies for existing drugs.
- Cost optimization initiatives to improve profitability.
What Are the Key Risks for ENZN?
- Financial-distress signal — its Altman Z-Score of 0.51 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-13.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from other pharmaceutical products.
- Regulatory changes affecting drug approvals.
- Patent expirations for key drugs.
- Economic downturn impacting healthcare spending.
- Limited liquidity due to OTC market trading.
What Are the Growth Opportunities for ENZN?
- Strategic Partnerships: Enzon could explore strategic partnerships with other pharmaceutical companies to expand the market reach of PegIntron and Vicineum. Collaborating with larger firms could provide access to broader distribution networks and marketing resources, potentially increasing sales and revenue. The market for strategic partnerships in the pharmaceutical industry is substantial, with numerous deals occurring annually. A successful partnership could lead to a significant boost in Enzon's financial performance.
- Market Expansion: Enzon could investigate opportunities to expand the market for its existing drugs into new geographic regions or patient populations. This could involve conducting clinical trials to demonstrate the efficacy of PegIntron and Vicineum in treating different conditions or patient demographics. The global market for pharmaceutical products is vast, and expanding into new markets could provide a significant growth opportunity for Enzon. This strategy would require careful planning and execution, but the potential rewards could be substantial.
- Lifecycle Management: Enzon can focus on lifecycle management strategies for PegIntron to extend its market exclusivity and revenue stream. This could involve developing new formulations, dosages, or delivery methods for the drug. By innovating and improving upon its existing product, Enzon can maintain a competitive edge and continue to generate revenue even as patents expire. The market for lifecycle management strategies in the pharmaceutical industry is significant, with companies constantly seeking ways to extend the lifespan of their blockbuster drugs.
- Acquisition of New Assets: Enzon could pursue the acquisition of new pharmaceutical assets to diversify its product portfolio and reduce its reliance on PegIntron and Vicineum. This could involve acquiring rights to new drugs, technologies, or intellectual property. By expanding its portfolio, Enzon can mitigate the risks associated with relying on a limited number of products. The market for pharmaceutical acquisitions is active, with numerous deals occurring annually. A successful acquisition could provide Enzon with new growth opportunities and enhance its long-term prospects.
- Cost Optimization: Enzon can focus on optimizing its operational costs to improve its profitability and financial performance. This could involve streamlining its operations, reducing its expenses, and improving its efficiency. By reducing its costs, Enzon can increase its profit margins and generate more cash flow. The market for cost optimization strategies in the pharmaceutical industry is significant, with companies constantly seeking ways to reduce their expenses and improve their bottom line. A successful cost optimization program could significantly improve Enzon's financial health.
What Opportunities Does ENZN Have?
- Strategic partnerships to expand market reach.
- Market expansion into new geographic regions.
- Lifecycle management strategies for existing drugs.
- Acquisition of new pharmaceutical assets.
What Threats Does ENZN Face?
- Competition from other pharmaceutical products.
- Regulatory changes affecting drug approvals.
- Patent expirations for key drugs.
- Economic downturn impacting healthcare spending.
What Are ENZN's Competitive Advantages?
- Existing marketing and distribution network for PegIntron.
- Established relationships with healthcare providers.
- Marketing agreement for Vicineum provides a revenue stream.
What Does ENZN Do?
Enzon Pharmaceuticals, Inc. was established in 1981 and is headquartered in Cranford, New Jersey. The company operates in the biotechnology sector, primarily focusing on marketing its existing drug products. Enzon's main marketed product is PegIntron, a drug used in the treatment of certain medical conditions. Additionally, the company has a marketing agreement related to Vicineum, another pharmaceutical product. Over the years, Enzon has evolved from a research-driven entity to one that concentrates on commercializing its existing portfolio. The company's strategy involves managing its current assets and seeking opportunities to maximize their value. Enzon's operations are primarily based in the United States, and it navigates the competitive landscape of the biotechnology industry by focusing on its niche products and marketing agreements. With a small number of employees, Enzon operates with a lean structure, emphasizing efficiency in its commercial activities.
What Products and Services Does ENZN Offer?
- Markets the drug product PegIntron.
- Maintains a marketing agreement relating to Vicineum.
- Focuses on commercializing its existing portfolio of pharmaceutical assets.
- Manages its current assets to maximize their value.
- Operates primarily in the United States.
- Navigates the competitive landscape of the biotechnology industry.
How Does ENZN Make Money?
- Generates revenue through the sale of PegIntron.
- Receives income from its marketing agreement related to Vicineum.
- Focuses on managing and commercializing its existing pharmaceutical assets.
- Operates with a lean structure to emphasize efficiency in its commercial activities.
What Industry Does ENZN Operate In?
Enzon Pharmaceuticals, Inc. operates within the biotechnology industry, a sector characterized by intense competition and rapid innovation. The market includes both large pharmaceutical companies and smaller biotech firms, all vying for market share. Enzon's focus on marketing existing drug products positions it as a niche player in this landscape. The biotechnology industry is driven by advancements in medical science, increasing healthcare spending, and regulatory approvals. However, it also faces challenges such as high research and development costs, patent expirations, and regulatory hurdles. Enzon's ability to navigate these challenges will be crucial for its long-term success.
Who Are ENZN's Key Customers?
- Patients who require treatment with PegIntron.
- Healthcare providers who prescribe PegIntron.
- Partners involved in the marketing and distribution of Vicineum.
ROE -14%Key Financial Metrics
Return on equity for Enzon Pharmaceuticals, Inc. stands at -13.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -2.2%, showing how much profit it generates from its asset base. A current ratio of 2.01 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -24.2%, the inverse of the P/E and a quick read on earnings relative to price.
How Enzon Pharmaceuticals, Inc. Is Valued
Enzon Pharmaceuticals, Inc. carries a market capitalization of $28.76M, placing it in the micro-cap category. Relative to its peer group, ENZN's quantitative score of 42/100 is below the peer average of 76/100.
F-Score 2/9Financial Health
Enzon Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.51 places it in the distress zone, a signal of elevated financial risk.
ENZN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Enzon's recent insider buying suggests those in the know see value, a classic sign of potential upside.
- Community chatter indicates growing optimism about Enzon's pipeline, with many highlighting potential catalysts.
- The market seems to be warming up to Enzon, with increased mentions in positive contexts across social trading platforms.
- Enzon's strategic partnerships are being viewed favorably, fueling speculation about future growth opportunities.
Bear Case
- Recent community sentiment reveals concerns about Enzon's long-term viability despite short-term gains.
- Insider activity, while showing buys, also includes significant selling, creating mixed signals and uncertainty.
- Market perception highlights Enzon's historical volatility, making some traders wary of a potential downturn.
- Bearish voices in the community point to potential regulatory hurdles facing Enzon's key projects, impacting future prospects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ENZN Latest News
No recent news available for ENZN.
ENZN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ENZN.
Price Targets
Wall Street price target analysis for ENZN.
ENZN MoonshotScore
What does this score mean?
The MoonshotScore rates ENZN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Richard L. Feinstein
CEO
Richard L. Feinstein currently serves as CEO of Enzon Pharmaceuticals, Inc. His background includes experience in managing pharmaceutical companies and overseeing the commercialization of drug products. He is responsible for guiding Enzon's strategic direction and overseeing its day-to-day operations. His leadership is focused on maximizing the value of Enzon's existing assets and exploring opportunities for growth. He manages a small team of employees and works to ensure the company's efficient operation.
Track Record: Under Richard L. Feinstein's leadership, Enzon Pharmaceuticals, Inc. has focused on marketing its existing drug product, PegIntron, and managing its marketing agreement for Vicineum. Key milestones include maintaining revenue streams from these assets and navigating the competitive landscape of the biotechnology industry. His strategic decisions have centered on optimizing operational costs and seeking opportunities to enhance the value of Enzon's portfolio.
ENZN OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Enzon Pharmaceuticals, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity due to low trading volume on the OTC market.
- Lack of regulatory oversight compared to major exchanges.
- Potential for information asymmetry due to limited disclosure.
- Higher risk of price manipulation and fraud.
- Uncertainty regarding the company's long-term viability.
- Verify the company's legal status and registration.
- Assess the availability and reliability of financial information.
- Evaluate the company's management team and their track record.
- Determine the company's compliance with regulatory requirements.
- Analyze the company's business model and competitive landscape.
- Assess the liquidity and trading volume of the stock.
- Understand the risks associated with investing in OTC stocks.
- The company was founded in 1981, indicating a long operating history.
- Enzon has a marketed drug product (PegIntron).
- The company has a marketing agreement relating to Vicineum.
- Richard L. Feinstein serves as the CEO.
What Investors Ask About Enzon Pharmaceuticals, Inc. (ENZN) — Healthcare
What does Enzon Pharmaceuticals, Inc. do?
Enzon Pharmaceuticals, Inc. is a biotechnology company that focuses on marketing its existing drug products. Its primary marketed product is PegIntron, and it also has a marketing agreement related to Vicineum. The company's business model involves managing and commercializing its current portfolio of pharmaceutical assets. Enzon operates primarily in the United States and navigates the competitive landscape of the biotechnology industry by focusing on its niche products and marketing agreements.
What do analysts say about ENZN stock?
Given Enzon Pharmaceutical's small market capitalization and OTC listing, formal analyst coverage is unlikely. Investors must conduct their own thorough due diligence, focusing on financial statements (if available), the prospects for PegIntron and Vicineum, and the risks inherent in OTC-traded securities. The company's negative profit margin and limited product portfolio warrant careful consideration. Independent research and risk assessment are crucial for any investment decision.
What are the main risks for ENZN?
Enzon Pharmaceuticals, Inc. faces several risks, including competition from other pharmaceutical products, regulatory changes affecting drug approvals, and patent expirations for its key drugs. Additionally, the company is exposed to economic downturns that could impact healthcare spending. As an OTC-traded company, Enzon faces additional risks related to limited liquidity, lack of regulatory oversight, and potential information asymmetry. Investors should carefully consider these risks before investing in ENZN.
What are the key factors to evaluate for ENZN?
Enzon Pharmaceuticals, Inc. (ENZN) holds an AI score of 42/100 (low). Not financial advice.
How frequently does ENZN data refresh on this page?
ENZN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ENZN's recent stock price performance?
Enzon Pharmaceuticals, Inc. (ENZN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Marketed drug product (PegIntron). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ENZN overvalued or undervalued right now?
Valuing Enzon Pharmaceuticals, Inc. (ENZN) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ENZN?
Before investing in Enzon Pharmaceuticals, Inc. (ENZN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's OTC status and limited disclosure.